沙库巴曲缬沙坦治疗糖尿病合并心血管并发症的研究进展

陈琳; 念馨; 蔡红雁

doi:10.12259/j.issn.2095-610X.S20241101

沙库巴曲缬沙坦治疗糖尿病合并心血管并发症的研究进展

doi: 10.12259/j.issn.2095-610X.S20241101

陈琳¹,
念馨^1, ,,
蔡红雁²

1.
昆明医科大学第一附属医院内分泌一科
2.
心脏内二科，云南昆明　650032

基金项目: 国家自然科学基金资助项目（82270372）；云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目（202201AY070001-066）；云南省“兴滇英才支持计划”名医专项基金资助项目（RLMY20220005）；云南省重大疑难疾病中西医临床协作试点基金资助项目（300073）；昆明医科大学科技创新团队基金资助项目（CXTD202209）

详细信息

作者简介:
陈琳（2000～），女，云南曲靖人，在读硕士研究生，主要从事内分泌与代谢性疾病研究及临床工作

通讯作者:
念馨，E-mail：nianxinkm@hotmail.com

中图分类号: R587.1
计量
- 文章访问数: 656
- HTML全文浏览量: 385
- PDF下载量: 33
- 被引次数: 0
出版历程
- 收稿日期: 2024-10-22
- 网络出版日期: 2024-11-18
- 刊出日期: 2024-11-25

Research Progress in the Treatment of Diabetes Mellitus with Cardiovascular Complications with Sacubitril Valsartan

Lin CHEN¹,
Xin NIAN^{1
, ,},
Hongyan CAI²

1.
Dept. of Endocrinology
2.
Dept 2. of Cardiology，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

摘要

摘要: 糖尿病由于多种因素常并发心血管并发症，心血管并发症也是糖尿病患者死亡的常见因素，因此，在改善糖尿病患者糖代谢同时也需控制心血管并发症。沙库巴曲缬沙坦是一种新型复合物，有着抑制脑啡肽酶和血管紧张素受体的双重作用，目前在临床上常作为心力衰竭患者的常用药物。近期的研究提示，沙库巴曲缬沙坦可能还存在着潜在的代谢益处，在改善糖尿病患者心功能的同时能改善血糖控制，有望成为糖尿病可常规使用的药物，带来心血管及代谢方面的益处。综述沙库巴曲缬沙坦在治疗糖尿病患者合并心血管疾病时的临床疗效及代谢益处。
- 沙库巴曲缬沙坦 /
- 脑啡肽酶 /
- 肾素血管紧张素系统 /
- 利钠肽 /
- 血糖
Abstract: Diabetes often coexists with cardiovascular complications, which are also a common cause of death in diabetes patients. Therefore, in addition to improving glucose metabolism, it is also necessary to control cardiovascular complications in diabetes patients. Sacubitril valsartan is a novel compound with dual actions of inhibiting neprilysin and angiotensin receptor, and it is commonly used as a heart failure drug in clinical practice. Recent studies suggest that sacubitril valsartan may also have potential metabolic benefits, improving cardiac function while improving glycemic control in diabetes patients, and it is expected to become a drug that can be used routinely in diabetes, bringing cardiovascular and metabolic benefits. This review focuses on the clinical efficacy and metabolic benefits of sacubitril valsartan in the treatment of diabetes patients with cardiovascular diseases.
- Sacubitril valsartan /
- Neprilysin /
- Renin angiotensin system /
- Natriuretic peptide /
- Blood sugar

HTML全文

参考文献(33)

[1]	李智宁,潘志琼. 沙库巴曲缬沙坦治疗慢性心力衰竭合并糖尿病患者的临床研究[J]. 糖尿病新世界,2022,25(10):69-72.
[2]	王险峰,徐涛. 沙库巴曲缬沙坦钠治疗心力衰竭伴2型糖尿病的临床效果[J]. 临床医学研究与实践,2019,4(14):50-51.
[3]	刘洋,吕媛媛. 替米沙坦与缬沙坦对原发性高血压病人胰岛素抵抗的影响[J]. 中西医结合心脑血管病杂志,2017,15(13):1615-1618. doi: 10.3969/j.issn.1672-1349.2017.13.023
[4]	Malek V,Gaikwad A B. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications[J]. Biomed Pharmacother,2017,90(6):752-759.
[5]	史云聪,和丽丽,白晓谊. 肾素-血管紧张素系统及脑啡肽酶抑制剂临床应用进展[J]. 临床荟萃,2020,35(5):476-480. doi: 10.3969/j.issn.1004-583X.2020.05.019
[6]	Abuissa H,Jones P G,Marso S P,et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials[J]. J Am Coll Cardiol,2005,46(5):821-826. doi: 10.1016/j.jacc.2005.05.051
[7]	Zhang Z,Liu C,Gan Z,et al. Improved glucose-stimulated insulin secretion by selective intraislet inhibition of angiotensin II type 1 receptor expression in isolated islets of db/db mice[J]. Int J Endocrinol,2013,2013:319586.
[8]	Carlsson P O,Berne C,Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats[J]. Diabetologia,1998,41(2):127-133. doi: 10.1007/s001250050880
[9]	马妮娜,沈潞华. 氯沙坦对高血糖合并高血压患者胰岛素敏感性的影响[J]. 临床合理用药杂志,2011,4(28):20-22.
[10]	潘利亚,张晓卉,尹新华. 糖尿病心肌病发病机制的研究进展[J]. 中国心血管杂志,2017,22(2):143-146. doi: 10.3969/j.issn.1007-5410.2017.02.015
[11]	Rubattu S,Gallo G. The natriuretic peptides for hypertension treatment[J]. High Blood Press Cardiovasc Prev,2022,29(1):15-21. doi: 10.1007/s40292-021-00483-5
[12]	杨淑莲,吴晓羽. 沙库巴曲缬沙坦的临床应用及其潜在作用[J]. 实用心脑肺血管病杂志,2020,28(5):82-86. doi: 10.3969/j.issn.1008-5971.2020.05.016
[13]	Jordan J,Stinkens R,Jax T,et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension[J]. Clin Pharmacol Ther,2017,101(2):254-263. doi: 10.1002/cpt.455
[14]	Cloro C,Zaffina I,Sacchetta L,et al. Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction[J]. Front Endocrinol (Lausanne),2022,13(10):1-9. doi: 10.3389/fendo.2022.940654
[15]	赵刚,张虹. 沙库巴曲缬沙坦应用于心血管疾病研究进展[J]. 安徽医药,2020,24(7):1273-1277. doi: 10.3969/j.issn.1009-6469.2020.07.001
[16]	Przezak A,Bielka W,Pawlik A. Hypertension and type 2 diabetes-the novel treatment possibilities[J]. Int J Mol Sci,2022,23(12):1-16.
[17]	Campbell D J. Long-term neprilysin inhibition - implications for ARNIs[J]. Nat Rev Cardiol,2017,14(3):171-186. doi: 10.1038/nrcardio.2016.200
[18]	Seferovic J P,Solomon S D,Seely E W. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control[J]. Ther Adv Endocrinol Metab,2020,11(24):1-9.
[19]	杨庭树. 慢性心力衰竭药物治疗的历程与进展[J]. 中华保健医学杂志,2022,24(2):81-86. doi: 10.3969/j.issn.1674-3245.2022.02.001
[20]	费美莹,姜东炬. 心力衰竭药物沙库巴曲缬沙坦的研究进展[J]. 心血管病学进展,2020,41(2):122-125.
[21]	Gamarra E,Baffoni C,Borretta G,et al. Reduction of insulin requirement after starting treatment with sacubitril/valsartan in a patient with diabetes treated with continuous subcutaneous insulin infusion (CSII): A case report[J]. J Diabetes Sci Technol,2018,12(6):1254-1255. doi: 10.1177/1932296818785644
[22]	Packer M. Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure[J]. Eur J Heart Fail,2018,20(6):973-977. doi: 10.1002/ejhf.1185
[23]	Seferovic J P,Claggett B,Seidelmann S B,et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: A post-hoc analysis from the PARADIGM-HF trial[J]. Lancet Diabetes Endocrinol,2017,5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6
[24]	de la Espriella-Juan R,Sanchis J,Bayes-Genis A,et al. Metabolic effects of sacubitril/valsartan: Are they relevant in clinical practice?[J]. Cardiovasc Diagn Ther,2018,8(4):549-551. doi: 10.21037/cdt.2018.07.05
[25]	van der Zijl N J,Moors C C,Goossens G H,et al. Valsartan improves beta-cell function and insulin sensitivity in subjects with impaired glucose metabolism: A randomized controlled trial[J]. Diabetes Care,2011,34(4):845-851. doi: 10.2337/dc10-2224
[26]	Bindom S M,Lazartigues E. The sweeter side of ACE2: Physiological evidence for a role in diabetes[J]. Mol Cell Endocrinol,2009,302(2):193-202. doi: 10.1016/j.mce.2008.09.020
[27]	Zhang Z,Liu C,Gan Z,et al. Improved glucose-stimulated insulin secretion by selective intraislet inhibition of angiotensin II type 1 receptor expression in isolated islets of db/db mice[J]. Int J Endocrinol,2013,2013(1):1-10.
[28]	Cole B K,Keller S R,Wu R,et al. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice[J]. Hypertension,2010,55(3):715-721. doi: 10.1161/HYPERTENSIONAHA.109.148049
[29]	McMurray J J,Holman R R,Haffner S M,et al. Effect of valsartan on the incidence of diabetes and cardiovascular events[J]. N Engl J Med,2010,362(16):1477-1490. doi: 10.1056/NEJMoa1001121
[30]	Zimmet P,Alberti K G,Magliano D J,et al. Diabetes mellitus statistics on prevalence and mortality: Facts and fallacies[J]. Nat Rev Endocrinol,2016,12(10):616-622. doi: 10.1038/nrendo.2016.105
[31]	McMurray J J,Gerstein H C,Holman R R,et al. Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored[J]. Lancet Diabetes Endocrinol,2014,2(10):843-851. doi: 10.1016/S2213-8587(14)70031-2
[32]	Wang R,Ye H,Zhao Y,et al. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: A systematic review and meta-analysis of randomised controlled trials[J]. BMC Med,2022,20(1):487. doi: 10.1186/s12916-022-02682-w
[33]	Esser N,Schmidt C,Barrow B M,et al. Insulinotropic effects of neprilysin and/or angiotensin receptor inhibition in mice[J]. Front Endocrinol (Lausanne),2022,13(6):1-14.

相关文章(20)

[1]	蒋慕蓉, 雷源钦, 张可, 刘秋梅, 杨文丽, 刘弘毅, 颜洁, 张清文. 云南部分米制品对血糖影响的研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231207
[2]	尚蒙, 高晓龙, 匡晓晖, 张曦, 张进, 王礼琳. 沙库巴曲缬沙坦在植入埋藏式心律转复除颤器慢性心力衰竭患者中的应用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231109
[3]	王艳飞, 马娟, 杨云巧. 沙库巴曲缬沙坦对射血分数降低合并低血压心衰患者的临床疗效及安全性的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221117
[4]	袁勇, 李心怡, 付燕, 朱燕. 昆明地区妊娠期妇女、婴幼儿维生素D水平分析及妊娠期空腹血糖水平与维生素D水平的关联性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220931
[5]	章体玲, 张伟华, 罗庆祎, 夏洪颖, 鲁一兵. 沙库巴曲缬沙坦治疗扩张型心肌病心力衰竭的疗效, 昆明医科大学学报.
[6]	王莉莉. 盐酸氨溴素注射液联合头孢哌酮钠舒巴坦治疗糖尿病合并肺炎患者临床症状及对肺功能的影响, 昆明医科大学学报.
[7]	林义临, 张宏, 丁筱雪. 脑啡肽酶抑制剂治疗慢性心衰的研究进展, 昆明医科大学学报.
[8]	苏虹, 孙洪丽, 杨君. 远程多位一体医疗管理在妊娠期糖尿病中的应用, 昆明医科大学学报.
[9]	朱荔, 丘红梅, 周晓芳, 蔡海刚, 刘开平, 周园媛. 血清CA19-9水平与2型糖尿病患者糖脂代谢的相关性, 昆明医科大学学报.
[10]	杨萍. 血浆脑利钠肽与原发性高血压靶器官损害的相关性研究, 昆明医科大学学报.
[11]	常露. 动脉粥样硬化模型大鼠血液生化指标变化, 昆明医科大学学报.
[12]	伏忠阳. 缬沙坦联合硝苯地平缓释片在原发性高血压疾病中的疗效观察, 昆明医科大学学报.
[13]	张红. 胰岛素瘤致低血糖1例报道, 昆明医科大学学报.
[14]	杨理伟. 滇西亚种树鼩血糖生理指标、胰岛素的测定及其初步分析, 昆明医科大学学报.
[15]	杨秋萍. 胰高血糖素样肽-1与糖尿病性骨质疏松症, 昆明医科大学学报.
[16]	熊煜欣. STZ小剂量多次与大剂量单次腹腔注射诱导糖尿病大鼠模型的研究, 昆明医科大学学报.
[17]	常利侠. 需要层次理论在糖尿病患者护理中的应用, 昆明医科大学学报.
[18]	曾希云. BIAsp30与BHI30胰岛素对老年2型糖尿病患者血糖控制能力的临床观察, 昆明医科大学学报.
[19]	卫梦南. 妊娠期糖尿病产后血糖转归与瘦素水平相关性研究, 昆明医科大学学报.
[20]	陈关芬. 缬沙坦联合胰激肽原酶治疗早期糖尿病肾病的临床评价, 昆明医科大学学报.